JGL has an attractive portfolio of generic drugs for countries with high growth rates in the pharmaceutical business, said Dunja Siuc Valković, Director of Global Business Development in JGL at today’s panel held as part of a conference dedicated to generic and bioequivalent drugs and drugs with an added value. This pharmaceutical company from Rijeka had an active role in the organisation and preparation of the joint 22nd Medicines for Europe and 19th IGBA global event held in Dubrovnik from 8 to 10 June 2016.
“JGL is focused on the growing markets of the MENA and ASEAN region. These are regions with high growth rates in the pharmaceutical business, and the segments in which we can offer an interesting portfolio are still not covered. Croatia’s accession to EU provided us with a stronger company perception on these markets where European quality still has a very positive image and is synonymous with high quality products,” said Dunja Siuc Valković, MD at a thematic panel on current developments and socio-economic trends affecting health protection in developing markets.
The former European Generic Association (EGA) now operates under the name Medicines for Europe and represents pharmaceutical companies that supply EU markets with generic and bioequivalent drugs. The Association’s annual conference was held in Croatia for the first time, and JGL, as a manufacturer from the host country, presented itself to the participants as an active participant in the global chain of generic pharmaceutical industry.
“As part of the strategy of realising JGL’s B2B business on the markets of the Middle East and Southeast Asia, the Iranian market represents a large potential. During our last visit to Iran, our company, with the know how in the technology of sterile solutions and experience in large markets such as Russia, was recognised as an attractive partner for Iranian companies”, said Siuc Valković.
The conference in Dubrovnik brought together the leaders of the European pharmaceutical industry with the aim of encouraging co-operation, discussion and dialogue regarding the key challenges of the future, sustainable approach to high quality generic and bioequivalent drugs for European patients. The topics addressed included the importance of improving the efficiency of health care systems and better representation of generic and bioequivalent drugs and drugs with an added value, the importance of stimulating greater market competition, and improving regulatory cooperation for a better approach to sustainable business models.